These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 8345791)
1. Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells. Edwards CM; Otal MP; Stacpoole PW Metabolism; 1993 Jul; 42(7):807-13. PubMed ID: 8345791 [TBL] [Abstract][Full Text] [Related]
2. Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat. Walli AK; Seidel D J Clin Invest; 1984 Sep; 74(3):867-79. PubMed ID: 6470142 [TBL] [Abstract][Full Text] [Related]
3. Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia. Sörös P; Böttcher J; Maschek H; Selberg O; Müller MJ Hepatology; 1998 Nov; 28(5):1199-205. PubMed ID: 9794902 [TBL] [Abstract][Full Text] [Related]
5. Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation". Yu L; Qiu S; Genest J Atherosclerosis; 1996 Jul; 124(1):103-17. PubMed ID: 8800498 [TBL] [Abstract][Full Text] [Related]
6. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein-X fifty years after its original discovery. Fellin R; Manzato E Nutr Metab Cardiovasc Dis; 2019 Jan; 29(1):4-8. PubMed ID: 30503707 [TBL] [Abstract][Full Text] [Related]
8. Control of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by very low density lipoproteins of subjects with hypertriglyceridemia. Gianturco SH; Gotto AM; Jackson RL; Patsch JR; Sybers HD; Taunton OD; Yeshurun DL; Smith LC J Clin Invest; 1978 Feb; 61(2):320-8. PubMed ID: 202612 [TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids. Iglesias A; Arranz M; Alvarez JJ; Perales J; Villar J; Herrera E; Lasunción MA Clin Chim Acta; 1996 Apr; 248(2):157-74. PubMed ID: 8740580 [TBL] [Abstract][Full Text] [Related]
10. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543 [TBL] [Abstract][Full Text] [Related]
11. Individual variation in the effects of dietary cholesterol on plasma lipoproteins and cellular cholesterol homeostasis in man. Studies of low density lipoprotein receptor activity and 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in blood mononuclear cells. Mistry P; Miller NE; Laker M; Hazzard WR; Lewis B J Clin Invest; 1981 Feb; 67(2):493-502. PubMed ID: 6257763 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
13. Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. al Rayyes O; Wallmark A; Florén CH Hepatology; 1997 Apr; 25(4):991-4. PubMed ID: 9096609 [TBL] [Abstract][Full Text] [Related]
14. The regulation of 3-hydroxy-3-methylglutaryl-CoA reductase activity, cholesterol esterification and the expression of low-density lipoprotein receptors in cultured monocyte-derived macrophages. Knight BL; Patel DD; Soutar AK Biochem J; 1983 Feb; 210(2):523-32. PubMed ID: 6305342 [TBL] [Abstract][Full Text] [Related]
15. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447 [TBL] [Abstract][Full Text] [Related]
16. Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density-lipoprotein-receptor activity in the human hepatoma cell line Hep G2. Cohen LH; Griffioen M; Havekes L; Schouten D; van Hinsbergh V; Kempen HJ Biochem J; 1984 Aug; 222(1):35-9. PubMed ID: 6089762 [TBL] [Abstract][Full Text] [Related]
17. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by reversible phosphorylation: modulation of enzymatic activity by low density lipoprotein, sterols, and mevalonolactone. Beg ZH; Reznikov DC; Avigan J Arch Biochem Biophys; 1986 Jan; 244(1):310-22. PubMed ID: 3004340 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of two different homogeneous assays for LDL-cholesterol in lipoprotein-X-positive serum. Fei H; Maeda S; Kirii H; Fujigaki S; Maekawa N; Fujii H; Wada H; Saito K; Seishima M Clin Chem; 2000 Sep; 46(9):1351-6. PubMed ID: 10973865 [TBL] [Abstract][Full Text] [Related]
19. Role of lipoproteins and 3-hydroxy-3-methylglutaryl coenzyme A reductase in progesterone production by cultured bovine granulosa cells. Savion N; Laherty R; Cohen D; Lui GM; Gospodarowicz D Endocrinology; 1982 Jan; 110(1):13-22. PubMed ID: 6274615 [TBL] [Abstract][Full Text] [Related]